For U.S. healthcare professionals only

In the hemophilia A
community, no two patients are the same

When finding a treatment for hemophilia A, your patients' individual needs as well as their lives outside the clinic should be taken into account.1

There are many characteristics that make each patient different1,2:

  • Physical activity and lifestyle
  • Bleeding phenotype
  • Pharmacokinetic (PK) profile
  • Infusion dose and frequency
  • Adherence and prophylaxis
  • Annualized bleed rate (ABR) and ABR for joint bleeds
  • Personal goals
  • Baseline characteristics
    (eg, age, weight)

Living with hemophilia A will always be an undeniable part of their reality—both the welcome and unwelcome moments. Your patients need treatment options that can help them navigate the many complexities of real life with hemophilia A.

Hear from a peer about the ADVATE active patient type

Watch Jonathan C. Roberts, MD, discuss ADVATE as a personalized treatment option that can help protect against bleeds for his patient living with hemophilia A who has an active lifestyle. Learn more about the active patient type with a helpful brochure available here.

Hear from a peer about the ADVATE high-risk bleed patient type

Watch Mark Reding, MD, discuss ADVATE as a prophylactic treatment option for his Hemophilia A patient who is at a high risk for bleeds. Learn more about high-risk bleed patients in a helpful brochure available here.

Selected Important Risk Information

Warnings & Precautions

Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.

Please see additional detailed important risk information below.

ADVATE has 15+ years of experience treating hemophilia A in the real world3

ADVATE is a third-generation, full-length molecule, similar to the factor VIII that occurs naturally in the body.3,4

Science beaker icon. ADVATE® [Antihemophilic Factor (Recombinant)] which has an established formulation.

Established formulation

with a later generation plasma/
recombinant factor VIII.3,4
DNA icon inside of a square.  ADVATE® [Antihemophilic Factor (Recombinant)] has an established clinical record.


clinical record.5-7
RX icon inside of a square. ADVATE® [Antihemophilic Factor (Recombinant)] is the most widely used factor VIII product.

The most widely used

factor VIII product with 33 billion IUs sold globally.8 Based on units sold, as of February 2019.
Microscope icon. ADVATE® [Antihemophilic Factor (Recombinant)] was studied in 15 prospective studies.

Extensively studied

with evidence spanning over 15 years with 15 prospective studies.3,4,8

Committed to advancing hemophilia A care

In 2003, ADVATE became the first recombinant factor VIII treatment free of blood-based additives. Since then, TAKEDA has made advancements with flexible dosing options, reconstitution with BAXJECT® system, and the introduction of myPKFiT® for PK-guided personalized dosing.3,8

ADVATE [Antihemophilic Factor (Recombinant)]: first recombinant factor VIII (rFVIII) made without added human or animal proteins.3,8
First rFVIII 3000-IU single-vial dose.8
First and only rFVIII with physical health-related quality-of-life results in the Prescribing Information.3
ADVATE with BAXJECT III® reconstitution system.8
BAXJECT II needleless transfer device.8
First and only rFVIII 1700-IU single-vial dose.8
First and only rFVIII 4000-IU single-vial dose and 2-mL diluent option (250 IU, 375 IU, 500 IU, 750 IU, 1000 IU, 1500 IU, and 1700 IU).3,8
myPKFiT for ADVATE receives approval from the FDA for patients 16 and older.8
ADVATE has an established safety profile
See the data
See ADVATE prophylaxis study results
Learn more
  1. Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):6.
  2. Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8(2):237-246. doi:10.1586/17474086.2015.1002465
  3. Advate. Prescribing information. Baxalta US Inc; 2018.
  4. Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4(2):186-201. doi:10.1002/biot.200800241
  5. Auerswald G, Thompson AA, Recht M, et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012;107(6):1072-1082. doi:10.1160/TH11-09-0642
  6. Khair K, Mazzucconi MG, Parra R, et al. Pattern of bleeding in a large prospective cohort of haemophilia A patients: a three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Haemophilia. 2018;24(1):85-96. doi:10.1111/hae.13361
  7. Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359-367. Published correction appears in J Thromb Haemost. 2012;10(6):1204.
  8. Takeda data on file.